Buenos Aires
Breast Cancer
Symposium

BA-BCS 2024

September 3 – 6, 2024

IFIBYNE Auditorium, FCEN-UBA

Program

Download PDF Program here

Registration
Welcome from organizers
Opening Conference
Chairs:
  • Gabriel Rabinovich, IBYME-CONICET, Buenos Aires, Argentina
  • Edith Kordon, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina.
 
Robert Clarke
University of Manchester, Manchester, UK
The role of cytokines in regulating cancer stem cells in therapy-resistance and metastasis
Welcome Reception at IFIBYNE
Session 1: Luminal breast cancer
Chairs:
  • Caroline Lamb, IBYME-CONICET, Buenos Aires, Argentina
  • María F. Rubio, IDIM-UBA-CONICET, Buenos Aires, Argentina.
9:30-10:00  Todd Miller. Medical College of Wisconsin Cancer Center, Milwaukee, USA.
Leveraging endocrine and metabolic vulnerabilities in ER+ breast cancer.
10:00-10:30 Joseph Jerry. University of Massachusetts, Amherst, USA.
A panel of normal breast epithelial cells from donors differing in breast cancer risk: variation in barriers to immortalization and estrogen signaling.
10:30-10:45 Abstract selected for oral presentation:
RUNX2 expression correlates with tumor progression in luminal breast cancer patients. Yamil D Mahmoud, IBYME-CONICET.
10:45-11:00 Discussion
Coffee Break 
Session 2: New treatments for Luminal and Her2+ breast cancer
Chairs:
  • Natalia Rubinstein, iB3, FCEyN, UBA, Buenos Aires, Argentina
  • Vanina Medina, BIOMED-CONICET, UCA, Buenos Aires, Argentina.
11:30-12:00 Jennifer Richer. University of Colorado, Aurora, USA.
AR action in ER+ breast cancer – preclinical and clinical trial updates.
12:00-12:30 Federico Waisberg. Instituto Fleming, Buenos Aires, Argentina.
New treatments and biomarkers in hormone resistant (HR+) breast cancer.
12:30-12:45 Abstract selected for oral presentation:
RInhibition of Rac1 activity enhances Tastuzumab sensitivity in Her2-positive breast cancer cells through cell cycle deregulation, Virginia Judith Wolos, Instituto de Oncología Ángel Roffo.
12:45-13:00 Discussion
Lunch and Posters

14:40-15:00 Sponsor presentation: LOBOV Científica

Session 3: Detection and treatment of TNBC
Chairs:
  • Roxana Schillaci, IBYME-CONICET, Buenos Aires, Argentina
  • Maria José Rico, Facultad de Ciencias Médicas, UNR, Rosario, Argentina.
15:00-15:30 Roger Chammas. Center for Translational Research in Oncology, University of São Paulo, Brazil.
miRNAs as biomarkers for early onset Triple Negative Breast Cancers.
15:30-16:00 Paolo Ceppi. University of Southern Denmark, Odense, Denmark.
Propionate suppresses epithelial-to-mesenchymal transition and reduces the aggressiveness of lung carcinoma, can we extrapolate to breast cancer?
16:00-16:30 Paolo Mandó. CEMIC, Buenos Aires, Argentina.
New therapeutic options for TNBC.
16:30-16:45 Abstract selected for oral presentation:
Enhancing Paclitaxel efficacy in triple negative breast cancer through DKC1 inhibition with R1D2-10, Roman Nicolas Vilarullo, Universidad Nacional de Quilmes.
16:45-17:00 Discussion
Coffe Break
Round Table 1 (Spanish)
Coordinadoras:
  • Mariana Salatino, IBYME-CONICET, Buenos Aires, Argentina
  • María Roqué, IHEM-CONICET, Mendoza, Argentina
Utilidad clínica de la búsqueda de marcadores circulantes en biopsia líquida, para el redireccionamiento y/o seguimiento de la carga tumoral en pacientes con cáncer de mama.
Adriana De Siervi. IBYME-CONICET y Oncoliq, Buenos Aires, Argentina.
Javier Stigliano. Hospital Nacional Prof. A Posadas, Haedo, Argentina.
Manglio Rizzo. Departamento Oncología, Hospital Universitario Austral, Pilar, Argentina.
Julieta Pandolfi. Anatomía Patológica. Lab. Secuenciación. Hospital Italiano de Buenos Aires, Argentina.
Diego Marzese. (participante virtual) Division of Surgical Oncology, Duke University School of Medicine (DUSM), Durham, USA.
Session 4:
Cancer Stem Cells and Tumor Initiation

Chairs:

  • Albana Gattelli, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina
  • Catalina Lodillinski, Instituto Ángel Roffo, Buenos Aires, Argentina.
9:30-10:00  Fariba Behbod. University of Kansas, Kansas City, USA.
Ductal carcinoma in situ: Transcriptional diversity and stemness.
10:00-10:30 Jochen Maurer. University Hospital RWTH, Aachen, Germany.
Cancer stem cells as disease models in research – opportunities and challenges.
10:30-11:00 William Muller. Rosalind and Morris Goodman Cancer Center, Montreal, Canada.
Oncogene-mediated regulation of tumor immune microenvironment in mouse models of human breast cancer
11:00-11:15 Discussion
Coffee Break and Posters
Session 5: Breast Cancer Genomics and Transcriptomics
Chairs:
  • Ignacio Schor, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina
  • Marianela Candolfi, INBIOMED, FMED, UBA, Buenos Aires, Argentina.
11:45-12:15 Martin Abba. UNLP, La Plata, Argentina.
Old questions, new omics tools.
12:15-12:45 Pedram Razavi. Memorial Sloan Kettering Cancer Center, New York City, USA.
Breast cancer genomics and resistance to CDK4/6i.
12:45-13:00 Gonzalo Gomez Abuin. Hospital Alemán, Buenos Aires, Argentina.
Utility of next generation sequencing in breast cancer.
13:00-13:15 Abstract selected for oral presentation:
Exploring the effects of non-coding somatic mutations in BAF complex deregulation and the malignant characteristics of triple-negative breast cancer, Pedro J. Salaberry, IFIBYNE-UBA-CONICET.
13:15-13:30 Discussion
Lunch and Posters
Session 6: immunotherapy and fighting treatment resistance
Chairs:
  • Georgina Coló, INIBIBB-UNS, Bahía Blanca, Argentina
  • Germán A. Gil, CIQUIBIC, UNC-CONICET), Córdoba, Argentina.
15:00-15:30 Adrian Lee. University of Pittsburgh, Pittsburgh, USA.
Endocrine resistance in breast cancer metastasis.
15:30-16:00 Dejan Juric. Massachusetts General Hospital, Boston, USA.
Novel PI3Ki inhibitors including mutant-selective PI3K inhibitors.
16:00-16:30 María Vivanco. CIC bioGUNE, Basque Research and Technology Alliance, Derio, Spain.
Breast Cancer heterogeneity and resistance to hormone therapy.
16:30-16:45 Abstract selected for oral presentation:
Preclinical and clinical role of MUC4/TNF axis in metastatic triple-negative breast cancer, Florencia Mauro, IBYME-CONICET.
16:45-17:00 Discussion
Coffe Brake and Posters

 

Round Table 2 (Spanish)
Coordinadoras:
  • Mario Rossi Universidad Austral, Pilar, Argentina
  • Pablo Mandó, CEMIC, Buenos Aires, Argentina
Jerarquización en investigación dentro de la carrera de formación de los médicos, experiencias en CEMIC, Fleming y Austral.
Manglio Rizzo. Servicio de Oncología Hospital Austral, Pilar, Argentina.
Fernando Petracci. Instituto Fleming, Buenos Aires, Argentina.
Estrella Levy. Instituto Fleming, Buenos Aires, Argentina.
Tango Concert
Tango Concert at Museo Nacional de Ciencias Naturales Bernardino Rivadavia (separate registration)
Session 7: Early detection and treatment
Chairs:
  • Giselle Peters, Instituto Ángel Roffo, Buenos Aires, Argentina
  • Leandro E. Mainetti, Facultad de Ciencias Médicas, UNR, Rosario, Argentina.
9:30-10:00  Vanesa Gottifredi. Instituto Leloir, Buenos Aires, Argentina.
Targeting the chromosomic instability induced by cancer therapy.
10:00-10:30 Catherine Park. University of California, San Francisco, USA.
Evolution of breast radiotherapy options for today’s early stage patients.
10:30-10:45 Adriana de Siervi. Oncoliq, CABA-Argentina.
miRNAs for early cancer detection in liquid biopsy.
10:45-11:00 Abstract selected for oral presentation
SPARC: a potential biomarker of the transition from in situ to Invasive breast cancer, Marianela Sciacca, Instituto de Oncología Ángel Roffo, Buenos Aires, Argentina.
11:00-11:15 Discussion
Coffee Break 
Session 8: Understanding and modeling breast cancer subtypes
Chairs:
  • Paola Rojas, IBYME-CONICET, Buenos Aires, Argentina
  • María T. Branham, IHEM-CONICET, Mendoza, Argentina.
11:45-12:15 Steffi Oestereich. University of Pittsburgh, Pittsburgh, USA.
Invasive lobular breast cancer – what’s different and why is this important?
12:15-12:45 Alana Welm. University of Utah, Salt Lake City, Utah, USA.
Using patient-derived models for drug discovery and functional precision oncology in advanced breast cancer.
12:45-13:00 Abstract selected for oral presentation:
RET receptor integrates tumor cell-adipocyte communication to promote breast cancer. Sabrina A. Vallone, IFIBYNE-UBA-CONICET.
13:00-13:15 Abstract selected for oral presentation:
Progesterone promotes triple-negative breast cancer metastasis through RANKL-expressing Treg cells. Tomas Dalotto, IBYME-CONICET.
13:15-13:30 Discussion
Lunch and Posters
Session 9: Improving life quality
Chair:
  • Mario Rossi, Universidad Austral, Pilar, Argentina.
  • Virginia Novaro, IBYME-CONICET, Buenos Aires, Argentina
15:15-15:45 Syril Pettit. Health and Environmental Sciences Institute (HESI), Washington DC, USA.
Addressing Cancer Therapy Related Adverse Effects – An Opportunity to Improve Quality of Life and Outcome for Patients.
15:45-16:00 Discussion
Closing Conference
Chairs:
  • Osvaldo Podhajcer, Instituto Leloir, CONICET, Buenos Aires, Argentina.
  • Mariana Salatino, IBYME-CONICET, Buenos Aires, Argentina.
16:00-17:00 Katherine Hoadley. UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA.
Molecular Characteristics of Metastatic Breast Cancer
17:00-17:15 Discussion and closing remarks by the organizers
Coffe Break
Round Table 3 (Spanish)
Coordinadores:
  • Virginia Novaro, IBYME-CONICET, Buenos Aires, Argentina
  • Federico Waisberg, Instituto A. Fleming, Buenos Aires, Argentina.
Navegación en el sistema de salud para pacientes con bajo y alto riesgo de cáncer de mama. Situación actual en la región Norte, Centro y Sur del país.
Alejandro Di Sibio. Coordinador del Programa Nacional de Control de Cáncer de Mama del Instituto Nacional del Cáncer, Buenos Aires, Argentina
Marcela Kober. Instituto Misionero del Cáncer, Posadas, Argentina.
Romina Yapur. Hospital Villa Regina de Río Negro y Centro Oncológico Integral, General Roca, Argentina.

© 2024 All Rights Reserved.